Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

NCT02211833 | Completed Phase 1

• 1 other identifier: 1216.5
• Study Type: interventional
• Target: 41
• Locations: 0 countries
• Sites: N/A

Brief Summary

Exploratory evaluation of safety, tolerability, pharmacokinetics (PK), maximum tolerated dose (MTD), and efficacy of BI 2536 administered in combination with pemetrexed

Conditions

Carcinoma, Non-Small-Cell Lung

Outcome Measures

Primary Outcomes (2)

• Maximum tolerated dose (MTD) of BI 2536 in combination with pemetrexed

  by occurrence of dose limiting toxicities (DLT)

  up to 3 weeks

• Number of patients with adverse events during combination therapy

  according to common terminology criteria for adverse events (CTCAE) 3.0

  up to 20 weeks

Secondary Outcomes (6)

• Objective tumor response after combination therapy

  up to 20 weeks

• Duration of objective tumor response after combination therapy

  up to 1 year

• Progression free survival (PFS)

  up to 2 years

• Overall survival

  up to 2 years

• Number of patients with abnormal laboratory findings

  up to 20 weeks

Study Arms (1)

BI 2536 with pemetrexed

EXPERIMENTAL

combination therapy phase may be followed by BI 2536 monotherapy for eligible patients

Drug: BI 2536; Drug: Pemetrexed

Interventions

BI 2536 DRUG

BI 2536 with pemetrexed

Pemetrexed DRUG

BI 2536 with pemetrexed

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pathologic or cytologic confirmed diagnosis of NSCLC
• Recurrent, advanced or metastatic NSCLC that had progressed following 1 prior chemotherapy regimen for advanced disease. Patients could have received prior adjuvant chemotherapy as long as the disease free interval was longer than 1 year.
• Measurable disease by 1 or more techniques (CT, MRI) according to RECIST criteria
• Male or female aged 18 years or older
• Life expectancy of at least 3 months
• Eastern Cooperative Oncology Group (ECOG) performance score 0-2
• Written informed consent that was consistent with International Conference on Harmonization (ICH) - Good Clinical Practice (GCP) guidelines

You may not qualify if:

• Treatment with an investigational drug in another clinical study within the 28 days prior to the start of therapy or concomitantly with this study
• Anti-cancer therapy for NSCLC (except radiotherapy for palliative reasons) within the 28 days prior to Day 1 of treatment period 1 of this trial
• Any persisting toxicities that were deemed to be clinically significant from the previous therapy
• Received more than 1 prior chemotherapy regimen for advanced disease (not including prior adjuvant therapy). Patients could have received prior epidermal growth factor receptor tyrosine kinase inhibitors
• Unwilling or unable to take folic acid and vitamin B12 supplementation
• Active brain metastases (stable for \<28 days, symptomatic, or requiring concurrent steroids). Patients who had received prior whole brain irradiation and whose brain metastases were stable according to the criteria above were not excluded
• Other active malignancy diagnosed within the past 3 years (other than non-melanomatous skin cancer and cervical intraepithelial neoplasia)
• Concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would have limited compliance with trial requirement or which were considered relevant for the evaluation of the efficacy or safety of the trial drug
• Unable or unwilling to interrupt concomitant administration of NSAIDS 5 days prior to the day of and up to 2 days after the administration of pemetrexed
• Received prior therapy with pemetrexed
• Absolute neutrophil count (ANC) ≤1 500/μL, platelet count ≤100 000/μL, or haemoglobin \<9 mg/dL
• Total bilirubin \>1.5 mg/dL (26 μmol/L), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2.5 x the upper limit of normal (ULN), except in cases of known liver metastasis where a maximum 5 x ULN was acceptable
• Serum creatinine level \>1.5 mg/dL and or creatinine clearance \<45 mL/min
• Sexually active and unwilling to use a medically acceptable method of contraception
• Pregnancy or breast feeding

Sponsors & Collaborators

• Boehringer Ingelheim: lead

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BI 2536; Pemetrexed

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Guanine; Hypoxanthines; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Glutamates; Amino Acids, Acidic; Amino Acids; Amino Acids, Peptides, and Proteins; Amino Acids, Dicarboxylic

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 7, 2014
• First Posted: August 8, 2014
• Study Start: October 1, 2006
• Primary Completion: February 1, 2009
• Last Updated: August 8, 2014

Record last verified: 2014-08